Pharming Group NV (PHARM) - Net Assets
Based on the latest financial reports, Pharming Group NV (PHARM) has net assets worth €264.64 Million EUR (≈ $309.40 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€473.79 Million ≈ $553.90 Million USD) and total liabilities (€209.14 Million ≈ $244.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pharming Group NV (PHARM) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €264.64 Million |
| % of Total Assets | 55.86% |
| Annual Growth Rate | 10.16% |
| 5-Year Change | 16.57% |
| 10-Year Change | 721.71% |
| Growth Volatility | 118.77 |
Pharming Group NV - Net Assets Trend (2005–2024)
This chart illustrates how Pharming Group NV's net assets have evolved over time, based on quarterly financial data. Also explore PHARM asset base for the complete picture of this company's asset base.
Annual Net Assets for Pharming Group NV (2005–2024)
The table below shows the annual net assets of Pharming Group NV from 2005 to 2024. For live valuation and market cap data, see PHARM company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €214.16 Million ≈ $250.38 Million |
+8.13% |
| 2023-12-31 | €198.05 Million ≈ $231.55 Million |
-3.22% |
| 2022-12-31 | €204.64 Million ≈ $239.24 Million |
+6.19% |
| 2021-12-31 | €192.72 Million ≈ $225.31 Million |
+4.89% |
| 2020-12-31 | €183.73 Million ≈ $214.80 Million |
+56.69% |
| 2019-12-31 | €117.26 Million ≈ $137.09 Million |
+66.00% |
| 2018-12-31 | €70.64 Million ≈ $82.58 Million |
+213.15% |
| 2017-12-31 | €22.56 Million ≈ $26.37 Million |
-21.91% |
| 2016-12-31 | €28.89 Million ≈ $33.77 Million |
+10.83% |
| 2015-12-31 | €26.06 Million ≈ $30.47 Million |
-28.18% |
| 2014-12-31 | €36.29 Million ≈ $42.43 Million |
+424.55% |
| 2013-12-31 | €6.92 Million ≈ $8.09 Million |
+168.36% |
| 2012-12-31 | €-10.12 Million ≈ $-11.83 Million |
-557.23% |
| 2011-12-31 | €-1.54 Million ≈ $-1.80 Million |
-111.46% |
| 2010-12-31 | €13.43 Million ≈ $15.70 Million |
-29.58% |
| 2009-12-31 | €19.07 Million ≈ $22.30 Million |
+9.33% |
| 2008-12-31 | €17.45 Million ≈ $20.40 Million |
-65.51% |
| 2007-12-31 | €50.58 Million ≈ $59.13 Million |
-23.11% |
| 2006-12-31 | €65.78 Million ≈ $76.91 Million |
+93.26% |
| 2005-12-31 | €34.04 Million ≈ $39.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pharming Group NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7446610304.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €7.77 Million | 3.63% |
| Other Comprehensive Income | €-201.83K | -0.09% |
| Other Components | €471.95 Million | 220.37% |
| Total Equity | €214.16 Million | 100.00% |
Pharming Group NV Competitors by Market Cap
The table below lists competitors of Pharming Group NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Universal Insurance Holdings Inc
NYSE:UVE
|
$927.72 Million |
|
Asiainfo Security Technologies Corp. A
SHG:688225
|
$927.76 Million |
|
Maccura Biotechnology Co Ltd
SHE:300463
|
$928.17 Million |
|
Guoguang Electric Co Ltd
SHE:002045
|
$928.45 Million |
|
Zhejiang Cayi Vacuum Container Co. Ltd.
SHE:301004
|
$927.26 Million |
|
Guangzhou Metro Design And Research
SHE:003013
|
$927.07 Million |
|
Matrix Design Co. Ltd. A
SHE:301365
|
$926.63 Million |
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
$926.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharming Group NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 198,054,587 to 214,163,388, a change of 16,108,801 (8.1%).
- Net loss of 10,644,363 reduced equity.
- Other comprehensive income increased equity by 1,660,294.
- Other factors increased equity by 25,092,870.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.64 Million | -4.97% |
| Other Comprehensive Income | €1.66 Million | +0.78% |
| Other Changes | €25.09 Million | +11.72% |
| Total Change | €- | 8.13% |
Book Value vs Market Value Analysis
This analysis compares Pharming Group NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.34x to 4.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €4.27 | €1.43 | x |
| 2006-12-31 | €7.58 | €1.43 | x |
| 2007-12-31 | €5.52 | €1.43 | x |
| 2008-12-31 | €1.89 | €1.43 | x |
| 2009-12-31 | €1.63 | €1.43 | x |
| 2010-12-31 | €0.54 | €1.43 | x |
| 2011-12-31 | €-0.03 | €1.43 | x |
| 2012-12-31 | €-0.14 | €1.43 | x |
| 2013-12-31 | €0.03 | €1.43 | x |
| 2014-12-31 | €0.09 | €1.43 | x |
| 2015-12-31 | €0.06 | €1.43 | x |
| 2016-12-31 | €0.07 | €1.43 | x |
| 2017-12-31 | €0.05 | €1.43 | x |
| 2018-12-31 | €0.11 | €1.43 | x |
| 2019-12-31 | €0.17 | €1.43 | x |
| 2020-12-31 | €0.27 | €1.43 | x |
| 2021-12-31 | €0.27 | €1.43 | x |
| 2022-12-31 | €0.29 | €1.43 | x |
| 2023-12-31 | €0.30 | €1.43 | x |
| 2024-12-31 | €0.31 | €1.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharming Group NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.71%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 1.81x
- Recent ROE (-4.97%) is above the historical average (-96.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -62.14% | -4409.63% | 0.01x | 1.20x | €-24.56 Million |
| 2006 | -37.11% | -12582.31% | 0.00x | 1.59x | €-30.99 Million |
| 2007 | -102.65% | -5161.16% | 0.01x | 3.30x | €-56.98 Million |
| 2008 | -209.09% | -3946.54% | 0.01x | 5.35x | €-38.22 Million |
| 2009 | -240.82% | -2925.18% | 0.02x | 4.20x | €-47.84 Million |
| 2010 | -518.84% | -9837.17% | 0.02x | 3.43x | €-76.41 Million |
| 2011 | 0.00% | -570.32% | 0.12x | 0.00x | €-22.01 Million |
| 2012 | 0.00% | -227.01% | 0.63x | 0.00x | €-30.85 Million |
| 2013 | -300.60% | -220.05% | 0.22x | 6.27x | €-21.49 Million |
| 2014 | -19.32% | -27.22% | 0.38x | 1.87x | €-10.64 Million |
| 2015 | -41.77% | -91.96% | 0.19x | 2.42x | €-13.49 Million |
| 2016 | -63.84% | -110.48% | 0.13x | 4.62x | €-21.33 Million |
| 2017 | -425.26% | -89.22% | 0.54x | 8.84x | €-98.18 Million |
| 2018 | 40.47% | 18.50% | 0.63x | 3.47x | €21.53 Million |
| 2019 | 34.58% | 21.41% | 0.74x | 2.18x | €28.82 Million |
| 2020 | 20.54% | 16.53% | 0.54x | 2.28x | €19.37 Million |
| 2021 | 8.30% | 8.43% | 0.48x | 2.06x | €-3.28 Million |
| 2022 | 6.68% | 6.65% | 0.48x | 2.08x | €-6.79 Million |
| 2023 | -4.93% | -4.30% | 0.53x | 2.15x | €-29.56 Million |
| 2024 | -4.97% | -3.71% | 0.74x | 1.81x | €-32.06 Million |
Industry Comparison
This section compares Pharming Group NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $108,877,000
- Average return on equity (ROE) among peers: 2.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharming Group NV (PHARM) | €264.64 Million | -62.14% | 0.79x | $927.29 Million |
| Galapagos N.V. (GLPG) | $108.88 Million | 2.76% | 0.32x | $1.85 Billion |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more